The Future of AAV Gene Therapy is Scalable

The gene therapy industry is fuelled by the desire to expand patient access to these novel, and potentially life-saving, treatments. However, for these treatments to become widely available, manufacturing technologies must keep pace with biological advances and offer robust, scalable and reliable platforms for cost-effective AAV production.

Here, we demonstrate that our proprietary plasmid free TESSA™ technology is fully scalable, delivers high titres (over 7E11 GC/mL) and exceptional packaging efficiencies (94% by analytical ultracentrifugation post purification) and infectivity (1.4E11 infectious units / mL) when used to manufacture AAV6 at 50L scale.